April 1, 2014 - Target Validation BioMarker Global AMP

A five-year FNIH plan to collaborate with the FDA, ten big drug companies, and eight non-profit organizations that focus on specific diseases, to unravel the molecular pathways that lead to Alzheimer’s, Type 2 diabetes, rheumatoid arthritis and lupus—and to investigate new methods to track a disease’s progress, that could provide early reads on how a drug is affecting it. The objective is to “ensure we expedite translation of scientific knowledge into next generation therapies.” The roughly $230 million is being spent over five years in the first round of the AMP project, and was split roughly evenly between the NIH and drug companies.